At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 68 enrolled
Drug / intervention
AFQ056 +1 moredrug
Likely dose
AFQ056 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Subject and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)
In Brief
A Phase 2 clinical trial evaluating AFQ056 and Placebo for Cocaine-related Disorder. Completed, enrolled 68 participants across 8 sites in 3 countries.
Detailed Summary
This study assessed whether AFQ056 had a beneficial effect by reducing cocaine use in Cocaine Use Disorder (CUD) patients as assessed by Timeline Follow-Back cocaine self-report.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCocaine-related Disorder
CountriesArgentina, Spain, Switzerland
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartDec 2017
Primary CompletionDec 2019
TodayJul 2026
First PostedAug 8, 2017
Enrollment StartDec 4, 2017
Primary CompletionDec 16, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.9 years ago
Interventions
AFQ056drug
50 mg and 100 mg tablets taken orally
Placebodrug
Matching placebo tablets taken orally BID